-
Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema
•
China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal injection suspension (ARVN001) in a patient with uveitis macular edema (UME) at the Boao Super Hospital in Hainan’s medical pilot zone. This marks the first application of suprachoroidal injection therapy in Lecheng, facilitated by the…
-
Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs
•
China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano (Shanghai) Technology Co., Ltd. The collaboration, focused on nucleic acid drugs, aims to provide comprehensive solutions ranging from raw materials to equipment and processes. Partnership Focus and ObjectivesSynthgene, a leading upstream raw material supplier for…
-
ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation
•
ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has raised an undisclosed amount of funding from Guangzhou LBP Medicine Science & Technology Co., Ltd. The collaboration will focus on advancing digital polymerase chain reaction (PCR) technology, including product research and development (R&D), manufacturing, and…
-
Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug candidate, GST-HG171, in adult patients with mild/common COVID-19. This marks a significant step forward in the development of…
-
Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study
•
China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the Center for Drug Evaluation (CDE) in China to conduct a Phase Ib clinical study assessing the safety, efficacy, pharmacokinetics, and pharmacodynamics of its EVER001. The drug candidate, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK)…
-
Boston Scientific Completes First Surgery with RotaPro in China
•
US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using its RotaPro rotational atherectomy system at Ruijin Hospital’s Hainan Hospital (Boao research-oriented hospital) branch. This procedure marks the first clinical application of the product in China, facilitated by the “first pilot, first trial” scheme, which…
-
Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for the first six months of the year. The firm reported RMB 1.464 billion ($204.3 million) in revenues, down 23.2% year-on-year (YOY). The decline was attributed to COVID-19 related lockdowns in the domestic market. Business Segment…
-
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
•
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement with US-based Meitheal Pharmaceuticals, Inc., and compatriot firm Hong Kong King-Friend Industrial Co., Ltd. The agreement grants the two companies exclusive rights to Shuangcheng’s paclitaxel for injection (albumin-bound, 100mg/vial) in the US market. Meitheal will…
